Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name tagraxofusp-erzs
Synonyms
Therapy Description

Elzonris (tagraxofusp-erzs) is a fusion protein consists of human interleukin 3 (IL3) and the first 388 amino acids of diphtheria toxin [DT(388)], which binds to IL3 receptors and subsequently inhibits protein synthesis, leading to cell death (PMID: 28479592). Elzonris (tagraxofusp-erzs) is FDA approved for use in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
tagraxofusp-erzs Elzonris DT(388)IL3 fusion protein|IL3R-targeting fusion protein SL-401 Elzonris (tagraxofusp-erzs) is a fusion protein consists of human interleukin 3 (IL3) and the first 388 amino acids of diphtheria toxin [DT(388)], which binds to IL3 receptors and subsequently inhibits protein synthesis, leading to cell death (PMID: 28479592). Elzonris (tagraxofusp-erzs) is FDA approved for use in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown aggressive NK-cell leukemia not applicable tagraxofusp-erzs FDA approved Actionable In a Phase I/II trial that supported FDA approval, Elzonris (tagraxofusp-erzs) treatment resulted in complete response/clinical complete response in 53.8% (7/13) of patients with untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN, also known as natural killer cell leukemia/lymphoma) with a median follow-up of 11.5 months, and 1 complete response and 1 clinical complete response in 15 patients with relapsed or refractory BPDCN (FDA.gov; NCT02113982). detail... detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT04216524 Phase II Cyclophosphamide + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab + Venetoclax tagraxofusp-erzs + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax tagraxofusp-erzs Mercaptopurine + Methotrexate + Prednisone + tagraxofusp-erzs + Venetoclax + Vincristine Sulfate Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting
NCT02268253 Phase II tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Recruiting
NCT02270463 Phase Ib/II tagraxofusp-erzs SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Completed


Additional content available in CKB BOOST